I-Mab Enters Secondment Agreement with ABio-X Holdings
Ticker: NBP · Form: 6-K · Filed: Aug 30, 2024 · CIK: 1778016
Sentiment: neutral
Topics: management-change, agreement
TL;DR
I-Mab inks a secondment deal with ABio-X Holdings, following Dr. Fu's interim CEO appointment.
AI Summary
I-Mab announced on August 30, 2024, that it entered into a Secondment Agreement with ABio-X Holdings, Inc. This agreement follows the Company Board's prior approval on July 13, 2024, to appoint Dr. Sean Xi-Yong Fu as Interim Chief Executive Officer.
Why It Matters
This filing details a new operational agreement between I-Mab and ABio-X Holdings, Inc., potentially impacting the company's management structure and strategic direction.
Risk Assessment
Risk Level: low — The filing is an informational update regarding an agreement and an interim appointment, not a financial event with immediate market-moving implications.
Key Players & Entities
- I-Mab (company) — Registrant
- ABio-X Holdings, Inc. (company) — Party to Secondment Agreement
- Dr. Sean Xi-Yong Fu (person) — Interim Chief Executive Officer
- July 13, 2024 (date) — Date of Company Board approval
- August 30, 2024 (date) — Filing date
FAQ
What is the purpose of the Secondment Agreement between I-Mab and ABio-X Holdings, Inc.?
The filing does not specify the exact purpose of the Secondment Agreement, only that it has been entered into.
When was Dr. Sean Xi-Yong Fu appointed as Interim CEO?
Dr. Sean Xi-Yong Fu was appointed as Interim CEO on July 13, 2024, as approved by the Company Board.
What is the relationship between I-Mab and ABio-X Holdings, Inc.?
The filing indicates a formal Secondment Agreement has been established between the two companies.
Is this filing related to a financial transaction?
No, this filing (Form 6-K) is an informational report regarding an agreement and an interim executive appointment, not a financial transaction.
What is the filing date of this report?
This report was filed on August 30, 2024.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-08-30 15:23:08
Key Financial Figures
- $50,000 — nt, he will receive a monthly salary of $50,000, subject to tax withholding to the exte
Filing Documents
- 2nd_agreement_abio-x_8.3.htm (6-K) — 25KB
- imab-ex99_1.htm (EX-99.1) — 64KB
- 0000950170-24-102291.txt ( ) — 89KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. I-MAB By : /s/ Joseph Skelton Name : Joseph Skelton Title : Chief Financial Officer Date: August 30, 2024